Prescription drug · ANDA
Prednisone NDC 68071-4685
Prednisone 20 mg/1 · Tablet · Oral · NuCare Pharmaceuticals,Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68071-4685-2 | 68071468502 | 21 TABLET in 1 BOTTLE (68071-4685-2)Marketed from Dec 31, 2018 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Prednisone
- Generic name (nonproprietary)
- prednisone
- Active ingredients
- Prednisone — 20 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- NuCare Pharmaceuticals,Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 085161
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 68071-4685_1ab8cfbf-d4a4-4937-e063-6294a90a34beSPL ID 1ab8cfbf-d4a4-4937-e063-6294a90a34beSPL set ID 7e541478-4a33-189f-e053-2a91aa0a6962RxCUI 312615UNII VB0R961HZTUPC 0368071468526
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468071468502followed by a unit qualifier and the quantityPackage 68071-4685-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Prednisone tablets, USP are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected ca…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 085161
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Prednisone | Prednisone 20 mg/1 | TabletOral | Actavis Pharma, Inc. | 0591-5443 |
| Prednisone | Prednisone 20 mg/1 | TabletOral | Northwind Health Company, LLC | 51655-242 |
| Prednisone | Prednisone 20 mg/1 | TabletOral | Proficient Rx LP | 71205-239 |
| Prednisone | Prednisone 20 mg/1 | TabletOral | QPharma, Inc. | 42708-105 |
| Prednisone | Prednisone 20 mg/1 | TabletOral | A-S Medication Solutions | 50090-2786 |
| Prednisone | Prednisone 20 mg/1 | TabletOral | A-S Medication Solutions | 50090-2789 |
| Prednisone | Prednisone 20 mg/1 | TabletOral | A-S Medication Solutions | 50090-2804 |